Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 4/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559136 | 0.81 | SIGMAR1 (0.50) | SIGMAR1HRH4POLBRXFP1USP2 | |
| SCHEMBL4559858 | 0.71 | SIGMAR1 (0.43) | SIGMAR1HRH4POLBRXFP1USP2 | |
| SCHEMBL4559728 | 0.70 | SIGMAR1 (0.51) | SIGMAR1HRH4POLBRXFP1USP2 | |
| SCHEMBL4559135 | 0.70 | SMN1; SMN2 (0.51) | SIGMAR1POLBALDH1A1TSHRHSD17B10 | |
| SCHEMBL4468180 | 0.69 | RXFP1 (0.66) | SIGMAR1POLBRXFP1ALDH1A1TSHR | |
| SCHEMBL4558443 | 0.69 | SIGMAR1 (0.50) | SIGMAR1HRH4POLBRXFP1USP2 | |
| Hydrochloric Acid SCHEMBL4460573 | 0.68 | RXFP1 (0.64) | SIGMAR1POLBRXFP1ALDH1A1TSHR | |
| SCHEMBL4559522 | 0.68 | SIGMAR1 (0.43) | SIGMAR1ALDH1A1TSHRREN | |
| SCHEMBL937500 | 0.67 | LMNA (0.71) | SIGMAR1HRH4RXFP1ALDH1A1TSHR | |
| SCHEMBL3349691 | 0.67 | TDP1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | SIGMAR1 218/4885HRH4 39/4885POLB 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.